Amphastar Pharmaceuticals Inc. (AMPH) stock falls on Q4 2025 Earnings

Amphastar Pharmaceuticals Inc. (AMPH) reported fourth-quarter 2025 revenue of $183.1 million, down 1.8% year-over-year and below the consensus revenue estimate of $194.3 million.

Key financial results:

Revenue: $183.1 million (down 1.8% YoY)

Gross profit: $85.7 million (down 1.1% YoY)

Operating profit: $35.6 million (down 21.1% YoY)

Net income attributable to common shareholders: $24.4 million (down 35.7% YoY)

Diluted earnings per share: $0.51 (down 31.1% YoY)

Cash flow and balance sheet highlights:

Cash from operating activities: $32.9 million (up 13.2% YoY)

Capital expenditures: $8.3 million (down 33.4% YoY)

Cash and cash equivalents: $170.2 million (up 12.3% YoY)

Total liabilities: $840.5 million (down 0.6% YoY)

Analyst expectations and market reaction:

Consensus EPS estimate: $0.94; reported diluted EPS: $0.51.

Shares moved sharply after the release, falling 17.3% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Amphastar Pharmaceuticals Inc. Insider Trading Activity

Amphastar Pharmaceuticals Inc. insiders have traded $AMPH stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $AMPH stock by insiders over the last 6 months:

FLOYD F. PETERSEN has made 0 purchases and 6 sales selling 22,342 shares for an estimated $591,072.
RONG ZHOU (SENIOR EVP, PRODUCTION CENTER) sold 9,787 shares for an estimated $256,379
RICHARD K PRINS sold 4,179 shares for an estimated $113,253

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Amphastar Pharmaceuticals Inc. Hedge Fund Activity

We have seen 112 institutional investors add shares of Amphastar Pharmaceuticals Inc. stock to their portfolio, and 148 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 407,092 shares (-58.3%) from their portfolio in Q4 2025, for an estimated $10,901,923
AMERICAN CENTURY COMPANIES INC added 376,751 shares (+130.6%) to their portfolio in Q4 2025, for an estimated $10,089,391
MARSHALL WACE, LLP added 363,216 shares (+41.6%) to their portfolio in Q4 2025, for an estimated $9,726,924
GOLDMAN SACHS GROUP INC added 315,481 shares (+130.8%) to their portfolio in Q4 2025, for an estimated $8,448,581
ALGERT GLOBAL LLC removed 267,772 shares (-68.2%) from their portfolio in Q4 2025, for an estimated $7,170,934
PRICE T ROWE ASSOCIATES INC /MD/ removed 238,426 shares (-86.6%) from their portfolio in Q4 2025, for an estimated $6,385,048
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 167,116 shares (+42.6%) to their portfolio in Q4 2025, for an estimated $4,475,366

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Amphastar Pharmaceuticals Inc. Analyst Ratings

Wall Street analysts have issued reports on $AMPH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 11/07/2025

To track analyst ratings and price targets for Amphastar Pharmaceuticals Inc., check out Quiver Quantitative's $AMPH forecast page.

Amphastar Pharmaceuticals Inc. Price Targets

Multiple analysts have issued price targets for $AMPH recently. We have seen 2 analysts offer price targets for $AMPH in the last 6 months, with a median target of $32.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $30.0 on 12/09/2025
Serge Belanger from Needham set a target price of $34.0 on 11/07/2025